Oxytocin

Grade A: Approved and proven

TL;DR: Oxytocin is FDA-approved in intravenous and intramuscular forms for obstetric indications: induction or augmentation of labor in appropriate antepartum settings (including preeclampsia, maternal diabetes, and premature rupture of membranes), management of second-trimester incomplete abortion, and postpartum control of uterine hemorrhage. Within these approved obstetric uses the evidence base is extensive and the benefit-risk profile is well-characterized. Intranasal oxytocin is not FDA-approved for any indication in the United States. A substantial body of randomized controlled trials has examined intranasal oxytocin for autism spectrum disorder, schizophrenia, PTSD, and anorexia nervosa; a 2024 multilevel meta-analysis of 28 ASD trials (N=726) found small effects on social functioning with no benefit on core non-social symptoms, and results across other behavioral indications have been largely negative or inconclusive. No controlled human safety data from long-term intranasal use have been submitted to the FDA.

Key Takeaways

Grade A: Approved and proven
FDA approved: FDA-approved (IV/IM) for obstetric use only; intranasal formulation is not approved for any indication in the United States.
Compounding: IV and IM oxytocin is FDA-approved for obstetric indications and is available as a generic. Intranasal oxytocin is not FDA-approved for any indication; compounded intranasal preparations are available through 503A pharmacies with a valid prescription but have not been evaluated by FDA for safety, efficacy, or quality in behavioral or neurological applications.

Oxytocin chemical structure — Structure via PubChem CID 439302

Mechanism

Oxytocin is an endogenous nine-amino acid neuropeptide that stimulates uterine smooth muscle contractions and postpartum uterine involution via G-protein coupled oxytocin receptors, and also acts centrally as a neuromodulator of social behavior and stress responses.

Evidence

Oxytocin is FDA-approved in intravenous and intramuscular forms for obstetric indications: induction or augmentation of labor in appropriate antepartum settings (including preeclampsia, maternal diabetes, and premature rupture of membranes), management of second-trimester incomplete abortion, and postpartum control of uterine hemorrhage. Within these approved obstetric uses the evidence base is extensive and the benefit-risk profile is well-characterized. Intranasal oxytocin is not FDA-approved for any indication in the United States. A substantial body of randomized controlled trials has examined intranasal oxytocin for autism spectrum disorder, schizophrenia, PTSD, and anorexia nervosa; a 2024 multilevel meta-analysis of 28 ASD trials (N=726) found small effects on social functioning with no benefit on core non-social symptoms, and results across other behavioral indications have been largely negative or inconclusive. No controlled human safety data from long-term intranasal use have been submitted to the FDA.

Safety and risks

For FDA-approved obstetric use, uterine hyperstimulation with strong or tetanic contractions is a critical risk that can cause uterine rupture, cervical lacerations, placental abruption, and fetal distress including hypoxia and death; continuous fetal and maternal monitoring is mandatory. Hyponatremia and water intoxication are serious and potentially fatal risks arising from oxytocin's intrinsic antidiuretic effect, particularly with high-dose or prolonged infusion; severe cases have caused maternal convulsions, coma, and death. Cardiovascular effects including tachycardia and, at excessive doses, arrhythmia and myocardial ischemia have been reported. The Institute for Safe Medication Practices classifies oxytocin among the 12 most hazardous hospital medications, and approximately 50% of maternity liability claims involve alleged oxytocin misuse. For intranasal off-label use, full human safety data are absent; potential hormonal and cardiovascular effects at non-physiologic doses are not characterized, and the risk-benefit profile for behavioral indications is not established.

Interactions

Use with prostaglandins or other uterotonics increases the risk of uterine hyperstimulation; concurrent use requires careful monitoring. Sympathomimetic vasopressors may produce additive hypertensive effects.

Federal compounding status

FDA-approved drug as of 2026-06-02.

An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

Federal status only, from public FDA records. State pharmacy-board rules vary and are not covered here. This is regulatory reporting, not legal advice. All compounds.

Compounding legality

IV and IM oxytocin is FDA-approved for obstetric indications and is available as a generic. Intranasal oxytocin is not FDA-approved for any indication; compounded intranasal preparations are available through 503A pharmacies with a valid prescription but have not been evaluated by FDA for safety, efficacy, or quality in behavioral or neurological applications.

Sources

Oxytocin is FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 1, 2026 by PeptideGrids editorial team (independently audited).